You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

nmCRPC

Showing 1 - 7 of 7
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Darolutamide, Enzalutamide and Apalutamide and How Well These

Not yet recruiting
  • Non-metastatic Castration-resistant Prostate Cancer
  • Whippany, New Jersey
    Bayer
Aug 25, 2023

Called DEAR, to Learn More About Treatment With Darolutamide,

Active, not recruiting
  • Non-metastatic Castration-resistant Prostate Cancer
  • Darolutamide (Nubeqa, BAY1841788)
  • +2 more
  • Whippany, New Jersey
    Bayer
Jan 13, 2023

Prostate Cancer Trial in Multiple Locations (Darolutamide 600 mg twice daily, Placebo 600 mg twice daily, Androgen deprivation

Recruiting
  • Prostate Cancer
  • Darolutamide 600 mg twice daily
  • +2 more
  • Multiple Locations, China
    Many Locations
Aug 2, 2022

Non-metastatic Castration-resistant Prostate Cancer Trial in India (Darolutamide (Nubeqa, BAY1841788))

Not yet recruiting
  • Non-metastatic Castration-resistant Prostate Cancer
  • Darolutamide (Nubeqa, BAY1841788)
  • Hyderabad, Andhra Pradesh, India
  • +22 more
Jul 29, 2022

Circulating Tumor Cells in High Risk and Early Metastatic

Recruiting
  • High Risk Prostate Carcinoma
  • +3 more
  • Blood collection
  • Bala-Cynwyd, Pennsylvania
  • +1 more
Jun 28, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Korea, Republic of, United States (Phase I and Phase II:

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Phase I and Phase II: LAE001/prednisone + afuresertib
  • Tucson, Arizona
  • +16 more
Nov 30, 2022

Prostate Cancer Trial in Baltimore (18F-DCFPyL Injection)

Withdrawn
  • Prostate Cancer
  • 18F-DCFPyL Injection
  • Baltimore, Maryland
    Johns Hopkins University
Dec 14, 2021